Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00720694 · ClinicalTrials.gov registry record · Phase 3

Study of Effectiveness and Safety of Extracorporeal Shock Wave Therapy (ESWT) for Treatment of Painful Heel Syndrome

A Phase 3 study of Plantar Fasciitis, sponsored by Storz Medical.

Completed
Registry status
Phase 3
Development phase
250
Enrollment target
6
Study locations

NCT00720694 is a Phase 3 study of Plantar Fasciitis that has completed, run by Storz Medical. The registered enrollment target is 250 participants, above the 67-participant average among 6 other Plantar Fasciitis trials with a reported enrollment target (273% higher). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00720694, a Phase 3 study of Plantar Fasciitis, has completed, sponsored by Storz Medical.

COMPLETED
Registry status
Phase 3
Development phase
250 participants
Enrollment target
6
Study locations

Study Summary

The purpose of this study is to determine if the Storz Duolith SD1 is more effective than placebo for treatment of heel pain syndrome for patients who have failed conservative treatment with other therapies.

Conditions Studied

Interventions

  • DEVICE Duolith SD1
  • DEVICE Sham Duolith SD1

Study Locations (6)

Connecticut

  • Connecticut Orthopedics Specialists - Hamden
  • Advanced Footcare Specialists of Connecticut, LLC - Newtown

California

  • Palo Alto Medical Fondation - Palo Alto

New York

  • Galli Podiatric Foot and Ankle Associates - New York

Ohio

  • Ankle and Foot Care Centers - Boardman

Washington

  • The Sports Medicine Clinic - Seattle

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2006-06
Phase Phase 3

Sponsor

Storz Medical

1 total trials

What the Registry Record Tells You About NCT00720694

The ClinicalTrials.gov registry entry for NCT00720694 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 67-participant average among 6 other Plantar Fasciitis trials with a reported enrollment target (273% higher). The listed sponsor is Storz Medical, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Plantar Fasciitis appearing as the primary indexed condition, and to 2 interventions - of which Duolith SD1 is the first listed.

NCT00720694 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Connecticut, California, New York.

Frequently Asked Questions

What is clinical trial NCT00720694 about?

NCT00720694 is a clinical study titled "Study of Effectiveness and Safety of Extracorporeal Shock Wave Therapy (ESWT) for Treatment of Painful Heel Syndrome". The purpose of this study is to determine if the Storz Duolith SD1 is more effective than placebo for treatment of heel pain syndrome for patients who have failed conservative treatment with other therapies.

What is the current status of trial NCT00720694?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 250 participants. The study started on 2006-06.

What conditions does trial NCT00720694 study?

This clinical trial studies the following conditions: Plantar Fasciitis.

What interventions are being tested in trial NCT00720694?

The interventions under investigation include: Duolith SD1 (DEVICE), Sham Duolith SD1 (DEVICE).

Who is sponsoring clinical trial NCT00720694?

This trial is sponsored by Storz Medical, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00720694 being conducted?

This trial has 6 study locations across California, Connecticut, New York, Ohio, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Plantar Fasciitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.